mRNA vaccine design for Epstein-Barr virus: an immunoinformatic approach.

Autor: Oladipo EK; Laboratory of Molecular Biology, Immunology and Bioinformatics, Department of Microbiology, Adeleke University, Ede, Osun State Nigeria.; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Akinleye TM; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria.; Department of Anatomy and Advanced Research Center for Tumor Immunology, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan, 47392 Republic of Korea., Adeyemo SF; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Akinboade MW; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Siyanbola KF; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Adetunji VA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Arowosegbe OA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Olatunji VK; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Adaramola EO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Afolabi HO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Ajani CD; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Siyanbola TP; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Folakanmi EO; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Irewolede BA; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Okesanya OJ; Faculty of Medicine, Department of Public Health and Maritime Transport, Laboratory of Hygiene and Epidemiology, University of Thessaly, Papakyriazi 22, Larissa, 41222 Greece., Ajani OF; African Centre for Disease Control and Prevention (African CDC), Addis Ababa, Ethiopia., Ariyo OE; Department of Medicine, Infectious Diseases and Tropical Medicine Unit, Federal Teaching Hospital, Ido-Ekiti, Ekiti State Nigeria., Jimah EM; Genomics Unit, Helix Biogen Institute, Ogbomosho, Oyo State Nigeria., Iwalokun BA; Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria., Kolawole OM; Department of Microbiology, University of Ilorin, Ilorin, 234031 Nigeria., Oloke JK; Department of Natural Science, Precious Cornerstone, Ibadan, 200132 Nigeria., Onyeaka H; School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, B15 2TT UK.
Jazyk: angličtina
Zdroj: In silico pharmacology [In Silico Pharmacol] 2024 Jul 24; Vol. 12 (2), pp. 68. Date of Electronic Publication: 2024 Jul 24 (Print Publication: 2024).
DOI: 10.1007/s40203-024-00244-x
Abstrakt: Epstein-Barr Virus (EBV), structurally similar to other herpes viruses, possess significant global health challenges as it causes infectious mononucleosis and is also associated with various cancers. Due to this widespread impact, an effective messenger RNA (mRNA) vaccine is paramount to help curb its spread, further underscoring the need for its development. This study, following an immunoinformatic approach, aimed to design a comprehensive mRNA vaccine against the EBV by selecting antigenic proteins, predicting Linear B-cell epitopes, cytotoxic T-cell lymphocyte (CTL) and helper T-cell lymphocyte (HTL) epitopes, and assessing vaccine characteristics. Seventy-nine EBV isolates from diverse geographical regions were examined. Additionally, the vaccine construct's physicochemical properties, transmembrane domains, solubility, and secondary structures were analysed. Molecular docking was conducted with Toll-Like Receptor 5 (TLR-5). Population coverage was assessed for selected major histocompatibility complex (MHC) alleles, and immune response was simulated. The result of this study highlighted a vaccine construct with high antigenicity, non-toxicity, and non-allergenicity and possessed favourable physicochemical properties. The vaccine's 3D structure is native-like and strongly binds with TLR-5, indicating a solid affinity with TLR-5. The selected MHC alleles provided broad universal population coverage of 89.1%, and the immune simulations suggested a robust and wide-ranging immunogenic response, activating critical immune cells, antibodies, and cytokines. These findings provide a solid foundation for further development and testing of the EBV candidate vaccine, offering potential solutions for combating EBV infections.
Competing Interests: Conflict of interestThe authors declare no competing interests.
(© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: